Rockstroh examines emerging challenges in HIV care, including COVID-19 and mpox, novel therapies, and lessons from Europe's care model. Explore the possibilities of shifting from disease management towards long-term remission and functional cure.

Timestamps:

00:00 – Introduction

00:45 – COVID-19 lessons

05:02 – Mpox challenges

07:42 – Novel therapies

12:56 – Improving care

15:39 – Remission or cure?

From HIV/hepatitis co-infections to haemophiliac cohorts, Rockstroh shares strategies for managing complex patient populations. Discover how antiretroviral therapy, multidisciplinary care, and lifestyle interventions work together to optimise outcomes.

Timestamps:

00:00 – Introduction

01:17 – HIV/hepatitis co-infection

05:43 – Cardiovascular risk

08:06 – Haemophiliac cohorts

11:47 – Multidisciplinary care

AMJ Podcast | Episode 4

Capivasertib in the Clinic: Strategies to Manage Adverse Events

This content was funded by AstraZeneca, and is intended for US Healthcare Professionals. Expert opinions are shared in this program and may differ from the approved capivasertib (TRUQAP®) labeling. Please see full Prescribing Information, including Patient Information when making treatment decisions.

Indication and Usage

Capivasertib (TRUQAP®) in combination with fulvestrant is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alteration as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.

Description

In this practical, case-based discussion, a breast oncology pharmacist and nurse practitioner walk through how they anticipate and manage the most common adverse events seen with capivasertib in HR-positive/HER2-negative advanced breast cancer.

Drawing on real-world clinic workflows, they share stepwise approaches to counseling, prophylaxis, and early intervention for diarrhea, rash, and hyperglycemia, including when to escalate monitoring or treatment and how to coordinate roles across the care team.

You'll hear communication scripts, tips for using tools such as stool diaries and home glucometers, and strategies to keep patients on therapy safely and confidently.

Chapters

• 00:00 – 03:24 | Introduction
• 03:24 – 05:18 | When to consider capivasertib
• 05:18 – 08:51 | Introducing adverse events
• 08:51 – 16:18 | Diarrhea management
• 16:18 – 20:35 | Rash management
• 20:35 – 25:07 | Hyperglycemia management
• 25:07 – 27:31 | Care team best practices
• 27:31 – 31:18 | Top Tips & Takeaways

Speakers:

Heather Moore – Breast Oncology Pharmacist, Duke University Medical Center

Sarah Donohue – Breast Oncology Nurse Practitioner, UCSF Health Breast Care Center

Select Safety Information About capivasertib (TRUQAP®) tablets

TRUQAP is contraindicated in patients with severe hypersensitivity to TRUQAP or any of its components.

Serious adverse reactions include hyperglycemia, including diabetic ketoacidosis and fatal outcomes; diarrhea; and cutaneous adverse reactions. Monitor fasting glucose and hemoglobin A1C levels regularly. May cause fetal harm when administered to a pregnant woman. Among the 355 patients who received TRUQAP in CAPItello-291, the most common (≥20%) adverse reactions, including laboratory abnormalities, were diarrhea (72%), cutaneous adverse reactions (58%), increased random glucose (57%), decreased lymphocytes (47%), decreased hemoglobin (45%), increased fasting glucose (37%), nausea and fatigue (35% each), decreased leukocytes (32%), increased triglycerides (27%), decreased neutrophils (23%), increased creatinine (22%), vomiting (21%), and stomatitis (20%).

Please see full Prescribing Information, including Patient Information for TRUQAP.

Jürgen Rockstroh discusses decades of progress in European HIV care, including treatment access, patient outcomes, early diagnosis, and the role of pre-exposure prophylaxis. Explore how European societies have standardised care to improve outcomes across diverse healthcare systems.

Timestamps:

00:00 – Introduction

00:57 – Key developments

03:18 – Earlier diagnosis

05:31 – Long-acting PrEP

07:58 – European societies

10:38 – Shifting clinical practice

In this rapid-fire episode, Jürgen Rockstroh answers key questions about HIV care, from common misconceptions and transformative developments to policy priorities and the European approach to treatment. A concise, high-value overview in just a few minutes.

From CFTR modulators to gene therapy, what's next in cystic fibrosis research? Peter Mogayzel examines future therapies, ongoing access challenges, and the crucial link between advocacy, innovation, and global health equity in cystic fibrosis care.

Timestamps:

00:00 – Introduction

01:05 - CFTR modulators

03:35 – Anti-inflammatory drugs

04:18 – mRNA therapy

04:53 – Side effects

07:13 – Access to care

08:37 – Exercise

10:00 – Final thoughts

What defines excellence in cystic fibrosis clinical care? Peter Mogayzel discusses the latest therapeutic guidelines, managing pulmonary exacerbations, the role of home monitoring, and how multidisciplinary teams work together to support patients in leading full, active lives.

Timestamps:

00:00 – Introduction

00:41 – Key guidelines

01:54 – Multisystem disease

02:32 – Pulmonary exacerbations

04:04 – Chronic medications

05:37 – Home monitoring

08:15 – Multidisciplinary care